We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03312777
Recruitment Status : Completed
First Posted : October 18, 2017
Last Update Posted : December 28, 2017
PRA Health Sciences
DF/Net Rearch
ITT Research Institute
Information provided by (Responsible Party):
Syntrix Biosystems, Inc.

Brief Summary:
This study evaluates the analgesic effect of Omnitram and tramadol during concurrent administration of paroxetine. Paroxetine administration is expected to diminish the analgesic effect of tramadol, but not Omnitram. Each participant will receive paroxetine before and during treatment with Omnitram, tramadol, and placebo.

Condition or disease Intervention/treatment Phase
Pain Drug: Omnitram Drug: Tramadol Drug: Placebo Phase 1

Detailed Description:

A randomized, double-blind, placebo-controlled study to investigating the steady-state oral pharmacokinetics and hypoalgesic effects of overencapsulated: 20 mg Omnitram (2x10 mg tablets), 50 mg tramadol (1x50 mg Ultram tablet), and placebo in male and female subjects made CYP2D6 deficient by paroxetine coadministration.

Sixty participants in normal health, 18 to 50 years of age, who meet the entry criteria, will be randomized to one of the three treatments in treatment segment 1. Each arm will ingest three consecutive 20 mg daily doses of paroxetine. Twelve hours after the first paroxetine dose, subjects will be randomized to one of the treatment sequences to ingest a total of 9 doses of Omnitram, tramadol, or placebo (one dose every 6 hours). Immediately before the 9th dose a blood sample will be collected to quantify plasma Omnitram, tramadol, and paroxetine. After the 9th study drug dose, six blood samples will be collected (1.0, 1.5, 2.0, 2.5, 4.0, and 8.0 hours after the 9th dose is administered) to quantify the Omnitram and tramadol. After the 9th dose, pain tolerance will be assessed with a cold pressor test (immersion of hand in ice cold water). Participants will washout for 11-15 days after treatment 1 and treatment 2. The study will analyze treatment side effects, the pharmacokinetics, and pain tolerance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Overencapsulation
Primary Purpose: Treatment
Official Title: A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Three Segment Cross-Over Study Investigating Oral Steady-State Pharmacokinetics And Hypoalgesic Effect Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects Made Cyp2d6 Deficient By Paroxetine
Actual Study Start Date : October 31, 2017
Actual Primary Completion Date : December 15, 2017
Actual Study Completion Date : December 22, 2017

Arm Intervention/treatment
Experimental: Omnitram
Oral Omnitram 20 mg (overencapsulated 10 mg tablets) administered every 6 hours for nine doses, coadministered with paroxetine.
Drug: Omnitram
Omnitram tablets overencapsulated

Active Comparator: Tramadol
Oral tramadol 50 mg (overencapsulated 50 mg tablet) administered every 6 hours for nine doses, coadministered with paroxetine.
Drug: Tramadol
Tramadol tablet overencapsulated

Placebo Comparator: Placebo
Oral placebo (overencapsulated microcrystalline) administered every 6 hours for nine doses, coadministered with paroxetine.
Drug: Placebo
Microcrystalline powder overencapsulated

Primary Outcome Measures :
  1. Cold Pressor Test - Cold Water Induced-Pain [ Time Frame: The test is performed on Day 3, shortly after the ninth (final) dose of study drug. ]
    The participant immerses a hand in cold water for a maximum of 3 minutes and reports the pain they experience using a "0 (no pain) to 10 (worst pain)" scale. Immersion of hand in ice cold water

Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: Participant report adverse events throughout study enrolment; investigators observe adverse events during all three 3 day inpatient treatment segments; laboratory safety labs are obtained on Day 3 of treatment segment 3 (the final treatment segment). ]
    Adverse events will include: 1) reports by participants; 2) observations by investigators; and 3) abnormal laboratory safety test results.

  2. Steady State Pharmacokinetics [ Time Frame: 8 hours ]
    Study drug plasma concentrations are assessed using specimens collected immediately before and after the 9th dose of each treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy males and females with normal vital signs: systolic blood pressure > 90 mm Hg and < 140 mm Hg; diastolic blood pressure > 45 mm Hg and < 90 mm Hg; pulse 40 to 100 beats per minute; respiratory rate 10 to 20 breathes per minute.
  2. Between the ages of 18 and 50 years of age.
  3. Able and willing to give informed consent
  4. Able to comply with all study procedures.
  5. If female, must not be of childbearing potential or must agree to use one or more of the following forms of contraception during screening and for 30 days following study drug administration: hormonal (e.g., oral, transdermal, intravaginal, implant or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); abstinence; or bilateral tubal ligation.
  6. Have adequate hematologic function as evidenced by the following screening results:

    WBC >3,500/mm3 and < 12,000/mm3 Platelet Count > 150,000/mm3 and < 540,000/mm3 Hemoglobin > 12.0 gm/dL and < 20.5 gm/dL

    Have adequate liver function as evidenced by the following screening results:

    AST (SGOT) ≤ 60 IU/L ALT (SGPT) men ≤ 83 IU/L women < 60 IU/L Alkaline Phosphatase ≤ 200 IU/L Total Bilirubin ≤ 1.2 mg/dL PT and PTT < 1.2 ULN

  7. Electrocardiogram (ECG) without clinically significant findings as determined by the PI.
  8. Have adequate renal function as evidenced by the following screening result:

    Glomerular filtration rate (GFR) calculated by Cockcroft-Gault formula >60 ml/min.

    Urinalysis demonstrating < +1 glucose, +1 ketones, and +1 protein.

  9. Negative pregnancy test within 1 week of study day 1 (women of childbearing potential only).
  10. Negative urine test for substances of abuse, including opiates, per CRU standards.
  11. Negative serology tests for HIV, hepatitis B surface antigen, and hepatitis C virus antibody.
  12. Body Mass Index (BMI) 18.0 to 32 kg/m.
  13. Cold pressor screening results as follows: 1) pain tolerance of > 20 seconds and <120 seconds.
  14. Cytochrome P450 2D6 (CYP2D6) genotype by Genelex consistent with intermediate metabolizer phenotype or normal metabolizer phenotype.

Exclusion Criteria:

  1. Oral temperature > 38°C or history of current illness.
  2. History of seizures, epilepsy, or recognized increase risk of seizure (e.g., head trauma, metabolic disorders, alcohol or drug withdrawal).
  3. History of cirrhosis or laboratory evidence of liver disease.
  4. Use of alcohol within 24 hours of day -1 until the end of the study; and grapefruit, grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), or grapefruit juice or grapefruit-related juices, or other medication, within 7 days of study drug administration and until the end of the study.
  5. History of previous anaphylaxis, severe allergic reaction to paroxetine, tramadol, codeine, or other opioid drugs.
  6. Use of MAO Inhibitors (including linezolid), Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and prescription or over-the counter (OTC) medications known to induce or inhibit drug metabolism, including CYP2D6, and other drugs that may affect the serotonergic neurotransmitter systems including, but not limited to, triptans, dextromethorphan, tricyclic antidepressants, bupropion, lithium, tramadol, dietary supplements such as tryptophan and St. John's Wort, and antipsychotics or other dopamine antagonists. These restrictions are to be maintained from 14 days before study day -1, until the subject completes the study.
  7. Any other unstable acute or chronic disease that could interfere with the evaluation of the safety of the study drug as determined by the principal Investigator in dialogue with the Sponsor Medical Monitor.
  8. Currently pregnant or breast feeding.
  9. Unlikely to comply with the study protocol.
  10. Known or suspected alcohol or drug abuse within the past 6 months.
  11. Received another investigational agent within 4 weeks of Day 1, or receiving any other investigational agent during this study.
  12. Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol, or obscure interpretation of the trial data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03312777

Layout table for location information
United States, Utah
PRA Health Sciences
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Syntrix Biosystems, Inc.
PRA Health Sciences
DF/Net Rearch
ITT Research Institute
Layout table for investigator information
Principal Investigator: Shawn L Searle, MD PRA Health Sciences
Study Director: Stuart Kahn, MD Syntrix Biosystems
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Syntrix Biosystems, Inc.
ClinicalTrials.gov Identifier: NCT03312777    
Other Study ID Numbers: Omni-Pain-102
First Posted: October 18, 2017    Key Record Dates
Last Update Posted: December 28, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Syntrix Biosystems, Inc.:
analgesia, Cytochrome P450 2D6
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents